Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07393282 | A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) | PHASE3 | NOT YET_RECRUITING | 270 | — | — | Mar 25, 2026 | Jul 22, 2033 | Mar 16, 2026 | - | — |
| Arm | Type | Description |
|---|---|---|
| Linvoseltamab | EXPERIMENTAL | - |
| Daratumumab | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Linvoseltamab | DRUG | Administered per the protocol |
| Daratumumab | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Eastern Cooperative Oncology Group performance status score ≤1 2. SMM diagnosis per IMWG criteria as defined in the protocol 3. Meets HR-SMM criteria by 1 of the risk models as defined in the protocol Key Exclusion Criteria: 1. Evidence of myeloma-defining events attrib...